

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 March 2003 (06.03.2003)

PCT

(10) International Publication Number
WO 03/017780 A1

(51) International Patent Classification⁷: **A23K 1/18,**
A01K 67/00, A01H 1/00

(21) International Application Number: PCT/US02/27198

(22) International Filing Date: 27 August 2002 (27.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/314,637 27 August 2001 (27.08.2001) US

(71) Applicant and

(72) Inventor: **KYLE, David, J.** [US/US]; 1801 Narberth
Road, Catonsville, Maryland 21228 (US).

(74) Agent: **GARRETT, Arthur, S.**; Finnegan, Henderson,
Farabow, Garrett & Dunner, LLP, 1300 I Street, N.W., Wash-
ington, DC 20005-3315 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 03/017780 A1

(54) Title: DELIVERY OF DISEASE CONTROL IN AQUACULTURE AND AGRICULTURE USING NUTRITIONAL FEEDS
CONTAINING BIOACTIVE PROTEINS PRODUCED BY VIRUSES

(57) Abstract: The present invention relates to the production of food products containing the biomass of a plant, animal or insect
expressing a heterologous protein. The food product can be administered as a means of delivering therapeutic proteins through
passive immunity.

**Delivery of Disease Control in Aquaculture and Agriculture Using Nutritional
Feeds Containing Bioactive Proteins Produced by Viruses**

BACKGROUND OF THE INVENTION

5 Field of the Invention

[001] This invention is directed to the use of edible materials which are used as feed components in aquaculture or agriculture, and which also contain exogenous peptides and/or antibodies or antibody fragments which will convey resistance or immunity to viral or bacterial pathogens or otherwise
10 improve the health and performance of the species consuming said edible materials. In particular, the exogenous peptides, proteins, and/or antibodies or antibody fragments are produced by cellular material infected by a virus that codes for the production of said peptides and/or antibodies or antibody fragments.

15 Related Art

[002] Certain plant products have been produced using specific genetic modification to express proteins and/or antibodies of therapeutic value. The group at the Boyce Thompson Institute at Cornell have cloned a viral coat protein into bananas so that when ingested by humans, this will be
20 equivalent to delivering an oral vaccine to those humans. This concept has not been extended to microbes.

[003] There are several plant biotech companies such as Meristem, Large Scale Biology, and Prodigene, which are now expressing certain

human therapeutic proteins in the plants including antibodies. Large Scale Biology is expressing proteins in tobacco plants using a tobacco mosaic virus as a vector to produce the protein of interest. The protein is then isolated and purified from the plant material and used for human therapeutic purposes. In
5 this way the plant genome itself is actually not modified, but rather the genome of the infecting virus carries the gene of interest.

[004] Recombinant microbes including bacteria, yeast and fungi have been used to produce human therapeutic proteins. However, such recombinant microbes have not been used for agricultural purposes
10 incorporating ingestion of the whole organism. In both the plant and microbial cases, the recombinant organism has simply been used as a factory, and the therapeutic protein is then isolated and purified prior to use.

[005] Certain plant products have been produced which contain proteins and/or antibodies of therapeutic value by infecting the plant with a
15 virus that expresses the protein of interest. Large Scale Biology has a series of patents protecting this technology but the purpose is to produce purified proteins for pharmaceutical purposes which requires an extensive purification procedure following harvesting of the plant material. These patents do not involve the use of the intact plant material as a source of both nutrition and
20 disease control except under the unusual condition that the pharmaceutical product is expressed in the fruit of the plant.

[006] Certain recombinant proteins have been produced in insect cells using an insect virus expression system (Baculovirus). Such proteins

are also produced in intact insect larvae following infection with modified Baculoviruses. In both cases, the insect cells or larvae are used as factories to produce the protein of interest, and the recombinant protein is then purified for pharmaceutical purposes. Insect cells or larvae infected with baculovirus
5 may be particularly useful in the expression of certain human therapeutic proteins because the post-translational modifications of the therapeutic proteins are similar to the post-translational modifications imparted upon expression in human cells.

[007] The Sindbis arbovirus was used to deliver high levels of gene
10 expression *in vivo* in non-host arthropod species without causing cytopathic effects in infected cells or impairing the development of the organism. A replication competent Sindbis virus containing the coding region of green fluorescent protein (GFP) produced productive infections when injected into insect larvae and pupae (Lewis, *et al.*, 1999). Thus, virus-mediated ectopic
15 gene expression has been accomplished in arthropods, a phylum that includes the classes Crustacea and Insecta.

[008] Antibiotic doping is used routinely in the aquaculture setting. Typically, the pure or semipure antibiotics are added directly to the water column or feeding system; however, crude fermentation broths, particularly
20 broths including cells, have not been used for any kind of therapeutic delivery system.

[009] Production of amino acids such as lysine typically involves a genetically modified microorganism which overproduces the amino acid of

interest and excretes it into the fermentation medium. The wastestream from such a fermentation would include biomass containing the amino acid, and this wastestream product could be used as a crude delivery form of the small molecule nutritive amino acid.

5 [010] A Baculovirus expression system is an efficient method for expressing proteins in insect cell culture. Baculovirus is in the family Baculoviridae, a diverse group of large double stranded DNA viruses that infect arthropods, including insects, arachnids, and crustaceans. Baculoviruses are species-specific and do not infect vertebrates nor
10 propagate in mammalian cells in culture.

SUMMARY OF THE INVENTION

 [011] The present invention provides for a composition of matter (the feed) and the use of this feed for the delivery of a therapeutic dose of a
15 bioactive peptide or protein.

 [012] In one embodiment, this invention provides an aquaculture or an agriculture feed containing plant biomass comprising one or more proteins, antibodies, or a combination thereof, where the proteins and antibodies are non-native to the plants. Preferably, the host plants are selected from
20 tobacco, corn, soybean, canola, sunflower, or any other cultivated crop. The plant genome itself may be modified to express the proteins or antibodies or antibody fragments. Alternatively, the plants may be infected with a virus or viruses which encode the proteins or antibodies or antibody fragments recombinantly. While in some cases the host and expressed protein may be

consumed together without further processing, preferably the plant material, not necessarily the fruit, would be modified in some way to make the material edible to non-human animals. Such a modification may include, but not be limited to, homogenizing, cooking, baking, extruding, solubilizing, or treatment
5 with enzymes.

[013] In another embodiment, this invention provides an aquaculture or an agriculture feed containing insect biomass comprising one or more proteins, antibodies, or a combination thereof, where the proteins and antibodies are non-native to the insects. Preferably, the insects are larval
10 stages of lepidoptera. The insect genome itself may be modified to express the proteins or antibodies or antibody fragments. Alternatively, the insects may be infected with a virus or viruses which encode the proteins or antibodies or antibody fragments and upon infection is expressed recombinantly. In a preferred mode, the insect material would be modified in
15 some way to make the material edible to non-human animals. Such a modification may include, but not be limited to, homogenizing, cooking, baking, extruding, solubilizing, or treatment with enzymes. This invention contemplates the use of the whole insect larvae or a portion thereof as a feed additive. This invention also contemplates the use of the larvae along with its
20 entire larval cultivation matrix, as all these materials may convey feed materials themselves. Such a larvae will typically contain the protein or proteins of interest but the purification steps are not necessary for its use in animal feeds.

[014] In another embodiment, this invention provides a method of delivering therapeutic proteins to a non-human animal comprising administering to a non-human animal a feed comprising a plant or insect expressing a non-native therapeutic protein. This method is particularly suitable for the non-human animal subjected to intensive agricultural practices, or for fish or shellfish in aquaculture. In a preferred mode, the therapeutic protein or proteins is (are) recombinant protein(s) expressed directly by the plant or insect. Alternatively, the plant or insect is infected by a recombinant virus which expresses the therapeutic protein recombinantly.

10 Preferred therapeutic proteins include a protein or proteins which inhibit(s) the growth or replication of a pathogen such as *Vibrio* species, or a protein or proteins which inhibit(s) shrimp viruses such as, but not limited to, Taura or White spot virus infection in shrimp, or a recombinantly expressed antibody or antibody fragments to viruses, or a protein which, when introduced orally to an animal will immunize said animal as in the case of an oral vaccine.

[015] In another, preferred, embodiment, this invention provides a method of transfecting crustaceans with non-native therapeutic proteins using baculovirus. This method is particularly suitable for crustaceans in aquaculture. Preferably, the crustaceans are Pacific white shrimp (*Penaeus vannamei*) and the baculovirus is Autographa californica nuclear polyhedrosis virus (AcNPV). The crustacean may be infected either by injection or orally, by incorporating the virus into the crustacean's food. The baculovirus may be

20

engineered to express green fluorescent protein (GFP) for monitoring infection.

DETAILED DESCRIPTION OF THE EMBODIMENTS

5 [016] The marine environment is filled with bacteria and viruses that can attack fish and/or shellfish. Infection by such bacteria or viruses can devastate intensive marine-based farms very quickly. The same is true for terrestrial environments where viral or bacterial infections can also dramatically limit farm productivity. One of the major disease control
10 problems in shrimp aquaculture today is infection by certain viruses (e.g., White Spot, Taura, etc.). Neither antibiotic, nor probiotic strategies will work in this situation, and shrimp cannot be vaccinated by methods analogous to those used for fish. Shrimp, like all crustaceans have only a rudimentary immune system so they are particularly susceptible to devastation by viral
15 attacks.

 [017] This invention provides a solution to this problem by providing a nutritional control method using the target animal's feed as the vector to deliver anti-viral antibodies or fragments thereof, directly to the shrimp. These "designer feeds" would deliver a therapeutic dose of antibody directly to the
20 gut of the shrimp. This approach is known as "passive immunity" because the antibody remains outside the host organism and simply prevents viral infestation through the gut wall. The invention envisions the use of transgenic multicellular organisms (plants, animals, insects, etc) to deliver the antibody to the gut of the target animal through the consumption of the transgenic

multicellular organism. Alternatively, the feed source itself may be infected with a host-specific virus that is engineered to produce the antibody, or fragment thereof, of interest in a multicellular organism that can be fed to the target animal. Alternatively, the feed material may deliver a portion of the virus (e.g. a coat protein) or fragment thereof in order to actively immunize the shrimp, other shellfish or finfish or terrestrial animal that consumes the feed.

[018] This invention provides advantages in production and delivery of the antimicrobial compounds or antibodies by packaging them in a plant or insect source compared to a fermentative source. Sterile fermentation is important for Drug-GMP compliance whereas the less-pure sources from plants or insects will be perfectly fine for animal use. Plants and insects are common elements in the food chain for either aquatic species or terrestrial species (Aquaculture or Agriculture). A second value in eukaryotic processing (e.g., by plants or insect cells) is that the post-translational modifications undertaken by these species may be more "native" compared to recombinant products from bacteria. One of the major problems with bacterial production of human proteins is that the microbially produced recombinant proteins are ineffective because of incorrect post-translation modifications.

[019] AcNPV is a Baculovirus commonly used in laboratory protein expression. It is shed from cells during early stages of infection by budding of the cell membrane; in later stages of infection, viruses are encased in intracellular occlusion bodies, which are large protein crystals. AcNPV is commonly used in the laboratory to infect insect cell culture lines. Vectors

and molecular biology supplies, and methods for Baculovirus expression vector systems, including AcNPV, are readily available from commercial suppliers.

[020] Antibodies or antibody fragments to desired targets, such as White Spot virus or Taura virus, may be prepared by routine immunization and selection of monoclonal antibody producing hybridomas, or by screening viral or bacterial expression libraries of immunoglobulin genes and gene fragments (Collagen, *et al.*). Nucleic acid sequences encoding the binding sites of the selected antibodies can be cloned using standard methods (Ausubel, *et al.*) and antibodies may be expressed from recombinant plants, animals or insects or cloned into viruses that infect the desired feed materials.

[021] There are a number of well known bactericidal and bacteriostatic peptides which will inhibit microbial growth and include, but are not limited to cecropins, peneadins, battenecins, callinectins, myticins, tachyplesins, clavanins, misgurins, pleurocidins, parasins, histones, acidic proteins, and lysozymes. These peptides may be made in a plant material such as tobacco, soybean, corn, sunflower, cotton, safflower, canola or any other agronomic species using recombinant methods well known to those in the art, and thus provided as a feed component to convey resistance or tolerance to infestation. Suitable plant material also includes macroalgae (Kelps) which are grown worldwide as a commodity feed crop in aquaculture. Macroalgae are the foodstuffs of many aquaculture species, and this invention contemplates recombinant production of therapeutic proteins in the natural or

farm diet of juvenile fish (e.g., half-grown catfish) as well as fish larva. Thus, within the contemplation of this invention are macroalgae or insects or other host organism that make up part of the food chain for the feeding of larvae, juveniles and adults in aquaculture, as well as the same life sequence in the terrestrial animal feeds (e.g. pigs, chickens, and cows).

[022] Edible materials can be any materials that are ingested. Preferably, edible materials may be of plant or animal (vertebrate or invertebrate) origin. Edible materials may be the whole plant or animal or any parts thereof. One embodiment of this invention would be where the plant or animal is genetically modified to produce the exogenous peptide and/or antibody or antibody fragments directly.

[023] Post harvest processing of some sort may be required to prepare the material for use as feeds. This invention contemplates normal (known) processes for converting the insect or plant material into feeds. Such normal process include homogenization followed by extrusion into pellets of various sizes depending on the application (e.g., larval, juvenile or adult). Other modes of preparation would include spray drying, fluid bed drying, or even providing the material as a liquid suspension.

[024] By "patient" it is meant any living animal, including, but not limited to, a human who has, or is suspected of having or being susceptible to, a pathologic condition, disease, or disorder, or who otherwise would be a subject of investigation relevant to a pathologic condition, disease, or disorder. Accordingly, a patient can be an animal that has been bred or

engineered as a model for any pathologic condition, disease, or disorder.

Likewise it can be a human suffering from, or at risk of developing, a pathologic condition, disease, or disorder. Similarly, a patient can be an animal (such as a farm animal, a dairy animal, a ranch animal, an animal that
5 lives under water, or an animal cultivated on land or in water for food or other commercial use, an experimental animal, or a pet animal) including a human, who is serving as a healthy control for investigations into pathologic conditions, diseases, or disorders.

10

EXAMPLES

[025] The invention as contemplated herein, is described in the following examples, but its utility is not limited to the examples provided.

[026] **Example 1. Incorporation of an antibody into a plant-based feed.** A particular viral or bacterial pathogen is chosen and used to
15 prepare monoclonal antibodies using procedures described in "Current Protocols in Immunology" or other procedures known to those skilled in this field. The white spot virus, for example, contains three major coat proteins, and antibodies or antibody fragments can be prepared to any or all of these proteins. Gene(s) coding for this antibody or an appropriate antibody
20 fragment (Fab) are isolated and amplified in an appropriate vector. The gene is spliced into a transformation vector suitable for plant transformation. The transformation vector is chosen so that the antibody will be overexpressed in the plant cellular biomass. The vector may be targeted to the edible portion of the plant (*i.e.*, seeds) so that normal harvesting methodologies can be used.

Alternatively, the vector may be targeted to the unused portion of the plant (stems and leaves) so that these less valued materials can be used as value added components to the crop plant without affecting the yield or quality of the normally harvested portion. The biomass in which the antibody is expressed is then used as a feed additive in such a way as to provide the antibody or antibody fragment directly to the animal, thus providing passive immunity.

[027] **Example 2. Expression of a bactericidal or bacteriostatic protein in a plant-based feed.** A bactericidal or bacteriostatic protein is chosen for the particular application. For example, proteins of the penaeidin class may be chosen for pathogenic control in shrimp. Penaeidins are members of a family of antimicrobial peptides isolated from crustaceans (e.g., *Penaeus* shrimp). Antimicrobial peptides may also come from insects and chelicerates and may include but are not limited to cecropins, peneadins, batenecins, callinectins, myticins, tachyplesins, clavanins, misgurins, pleurocidins, parasins, histones, acidic proteins, and lysozymes. The gene for the chosen protein or peptide is either isolated from the original source, an amplification source, or it can be made synthetically. The gene is spliced into a transformation vector suitable for plant transformation. The transformation vector is chosen so that the antibody will be overexpressed in the plant cellular biomass. The vector may be targeted to the edible portion of the plant (i.e., seeds) so that normal harvesting methodologies can be used. Alternatively, the vector may be targeted to the unused portion of the plant (stems and leaves) so that these materials can be used as value added

components to the crop plant without affecting the yield or quality of the normally harvested portion. This biomass is then used as a feed additive in such a way as to provide the bactericidal protein directly to the animal thus providing resistance to that particular pathogen.

- 5 [028] **Example 3. Incorporation of a gene for an antibody or antibody fragment into a plant-based virus and use of the infected plant material as feed.** A particular viral or bacterial pathogen is chosen and used to prepare monoclonal antibodies using procedures described in "Current Protocols in Immunology" or other procedures known to those skilled in this
- 10 field. Gene(s) coding for this antibody or an appropriate antibody fragment (Fab) are isolated and amplified in the appropriate vector. The gene is spliced into the genome of a selected plant virus such as tobacco mosaic virus (TMV) or cauliflower mosaic virus (CMV). This virus is then used to infect a plant (mature or seedling). As the virus replicates in the plant material it will
- 15 express the antibody or antibody fragment directly in the plant material. The entire plant can then be harvested and used directly as feed material. Alternatively, the plant material may be homogenized and extruded into pellets suitable for feed applications. The viruses should not be a concern in feeding , since they will not infect the animals consuming the feed, but to the
- 20 extent there is a concern, they can be inactivated by high temperature or other procedures familiar to those experts in the field prior to use of the plant material as feeds.

[029] **Example 4. Incorporation of a gene for a bactericidal or bacteriostatic protein into a plant-based virus and use of the infected plant material as feed.** A bactericidal or bacteriostatic protein is chosen for the particular application. For example, proteins of the penaeidin class may be chosen for pathogenic control in shrimp. Penaeidins are members of a family of antimicrobial peptides isolated from crustaceans (e.g., *Penaeus* shrimp). Antimicrobial peptides may also come from insects and chelicerates and may include but are not limited to cecropins, peneadins, battenecins, callinectins, myticins, tachypleins, clavanins, misgurins, pleurocidins, parasins, histones, acidic proteins, and lysozymes. The gene for the chosen protein or peptide is either isolated from the original source, an amplification source, or it can be made synthetically. The gene is spliced into the genome of a selected plant virus such as tobacco mosaic virus (TMV) or cauliflower mosaic virus (CMV). This virus is then used to infect a plant (mature or seedling). As the virus replicates in the plant material it will express the protein directly in the plant material. The entire plant can then be harvested and used directly as feed material. Alternatively, the plant material may be homogenized and extruded into pellets suitable for feed applications. The viruses can be inactivated by high temperature or other procedures familiar to those experts in the field prior to use as feeds.

[030] **Example 5. Incorporation of a gene for an antibody or antibody fragment into an insect-based virus and use of the infected insect material as feed.** A particular viral or bacterial pathogen is chosen

and used to prepare monoclonal antibodies using procedures well known to experts in this field. Gene(s) coding for this antibody or an appropriate antibody fragment (Fab) are isolated and amplified in the appropriate vector. The gene is spliced into the genome of a selected insect virus such as baculovirus. This virus is then used to infect insect larvae. As the virus replicates in the larval insect will express the antibody or antibody fragment directly in the larval cells. The entire larvae can then be harvested and used directly as feed material. Alternatively, the larvae may be homogenized and extruded into pellets suitable for feed applications. The viruses can be inactivated by high temperature or other procedures familiar to those experts in the field prior to use as feeds.

[031] **Example 6. Incorporation of a gene for a bacteriostatic or bactericidal protein into an insect-based virus and use of the infected insect material as feed.** A bactericidal or bacteriostatic protein is chosen for the particular application. For example, proteins of the penaeidin class may be chosen for pathogenic control in shrimp. Penaeidins are members of a family of antimicrobial peptides isolated from crustaceans (e.g., *Penaeus* shrimp). Antimicrobial peptides may also come from insects and chelicerates and may include but are not limited to cecropins, peneadins, battenecins, callinectins, myticins, tachyplesins, clavanins, misgurins, pleurocidins, parasins, histones, acidic proteins, and lysozymes. The gene for the chosen protein or peptide is either isolated from the original source, an amplification source, or it can be made synthetically. The gene is spliced into the genome

of a selected insect virus such as baculovirus. This virus is then used to infect insect larvae. As the virus replicates in the larvae it will express the protein directly in the larval tissues. The entire larva can be harvested and used directly as feed material. Alternatively, the larvae may be homogenized and extruded into pellets suitable for feed applications. The viruses can be inactivated by high temperature or other procedures familiar to those experts in the field prior to use as feeds.

[032] Example 7. Incorporation of a gene for a therapeutic protein into baculovirus and the use of the infected material as feed.

Pacific white shrimp (*Penaeus vannamei*) were transfected orally with an engineered baculovirus (AcNPV-eGFP) to express GFP as a fusion protein. The Bacmid Bac-to-Bac® Baculovirus Expression system (Invitrogen) was utilized for cloning and transfection. A 720 kb fragment containing GFP was fused to the polyhedron (pPolh) promoter and flanked by Xho I sites 3' to pPolh. Using methods described in the Invitrogen product literature, Sf9 insect cells were transfected with the recombinant baculovirus. After 72 hours, plaque formation was visually confirmed, and 70 ml culture fluid medium was pelleted at 100 g for 5 minutes at 4°C. The resulting cell pellet was maintained at 4°C until it was subsequently used for oral infection. The corresponding resulting supernatant fluid was centrifuged for 2 hours at 80,000 g at 4°C on a 27% sucrose gradient to yield purified virus. This sucrose-purified virus pellet was maintained at 4°C until it was subsequently used for oral infection.

[033] Shrimp isolation chambers consisting of 3-qt containers filled with 30 ppt salinity dechlorinated water were provided with air stones for oxygenation. Three one-gram shrimp were placed in each container and allowed to acclimatize overnight.

5 [034] The following procedures were performed within 30 minutes prior to feeding the shrimp. A pellet matrix was prepared by first adding 100 mg of alginic acid (Sigma) to 10 ml of distilled deionized water (ddH₂O) in a beaker and heating to 40 °C while stirring. After the gel began to form, 150 mg of starch (Sigma) was added. The solution was allowed to mix for a
10 minute before addition of 500 mg of krill meal. While continuing to stir the solution, the heat source was removed.

[035] An aliquot of pellet matrix (500 µl) was combined with either 5 µl of the infected cell pellet or 5 µl of sucrose-purified virus, and gently mixed with vortex mixer. The infected pellet matrix was aspirated into a tuberculin
15 syringe to which a 21-gauge needle was subsequently attached. A formation solution was formed by dissolving 5 grams of calcium chloride (J.T. Baker) and 1 gram of sodium chloride (Research Organics) in 100 ml of ddH₂O. While the formation solution was stirring slowly, the matrix was squeezed through the needle into the solution to form tubular pellets. Pellets formed
20 immediately upon impact in solution and a spatula was used to clean the needle between pellets. Pellets appeared to be 25-30 µl in volume. The pellets were washed in 10% NaCl and added to the shrimp isolation

containers. The shrimp immediately consumed the pellets, and were fed to satiation. Each shrimp consumed approximately one pellet.

[036] Seventy two hours after consuming the virally infected matrix, the shrimp were placed in a petri dish and observed on a Dark Reader® transilluminator (Claire Chemical Research). Shrimp expressing GFP exhibited a greenish glow (Figure 1). Uninfected shrimp demonstrated no fluorescence. The recombinant GFP-tagged baculovirus observed at 72 h was located specifically within the hepatopancreas area in the cephalothorax (Figure 1).

10 [037] **Example 8. Vaccination using feeds.** An antigen characteristic to a particular pathogen is chosen as is required by the animal and circumstances. For example, a viral coat protein or component thereof, or an infectious bacterial protein, or a component thereof is chosen. The gene coding for the protein is isolated and incorporated into a vector suitable
15 for use in the plant or insect of choice for production. The transformation vector is chosen so that the protein will be overexpressed in the plant, animal or insect cell biomass or in a virus infecting the plant, animal or insect biomass. This biomass is then used as a feed additive in such a way as to provide the viral or bacterial or fungal protein directly to the animal thus
20 stimulating an immunological response to that particular pathogen. The microbial component may enter the body of the animal in the digestive tract, or otherwise through contact in the air or water.

References

Ausubel, *et al.*, eds., (1987 and periodic supplements) *Current Protocols in Immunology*, Wiley-Interscience.

Bac-to-Bac Baculovirus expression systems manual. Invitrogen Life Technologies. Cat. No. 10359-016

Chalfie, M., Tu, Y., Euskirchen, G., Ward, W.W., and Prasher, D.C. (1994) Green Fluorescent Protein as a Marker for Gene Expression. *Science*. 263: 802-805.

Collagen, *et al.*, eds. (1991 and periodic supplements) *Current Protocols in Immunology*, Wiley-Interscience.

Inoue, S., and Tsuji, F.I. (1994) *Aequorea* green-fluorescent protein: Expression of the gene and fluorescence characteristics of the recombinant protein. *FEBS Letters*. 341: 277-280.

Lewis, David L., De Camillis, Mark A., Brunetti, Craig R., Halder, G., Kassner, Victoria A., Selegue, J.E., Higgs, S., and Carroll, S.B. (1999) Ectopic gene expression and homeotic transformations in arthropods using recombinant Sindbis viruses. *Current Biology* 9:1279-1287.

Prasher, D.C., Eckenrode, V.K., Ward, W.W., Prendergast, F.G., and Cormier, M.J. (1992) Primary structure of the *Aequorea victoria* green-fluorescent protein. *Gene*. 111: 229-233.

WHAT IS CLAIMED IS:

1. An aquaculture feed containing biomass of an organism selected from plants, animals and insects comprising one or more proteins, antibodies, antibody fragments, or a combination thereof, wherein said proteins and antibodies are non-native to the organism which is the source of the biomass.
2. The aquaculture feed as claimed in claim 1, wherein the organism expresses the proteins or antibodies recombinantly.
3. The aquaculture feed as claimed in claim 1, wherein the organism is infected with viruses which encode the proteins or antibodies expressed recombinantly.
4. An agriculture feed containing biomass of an organism selected from plants, animals and insects comprising one or more proteins, antibodies, antibody fragments, or a combination thereof, wherein said proteins and antibodies are non-native to the organism which is the source of the biomass.
5. The agriculture feed as claimed in claim 4, wherein the organism expresses the proteins or antibodies recombinantly.
6. The agriculture feed as claimed in claim 4, wherein the organism is infected with viruses which encode the proteins or antibodies expressed recombinantly.

7. A human food containing biomass of an organism selected from plants, animals or insects comprising one or more proteins, antibodies, antibody fragments, or a combination thereof, wherein said proteins and antibodies are non-native to the organism which is the source of the biomass.

8. The human food as claimed in claim 7, wherein the organism expresses the proteins or antibodies recombinantly.

9. The human food as claimed in claim 7, wherein the organism is infected with viruses which encode the proteins or antibodies expressed recombinantly.

10. The agricultural feed as claimed in claim 4, or human food as claimed in claim 7, wherein the organism is an agronomic plant selected from tobacco, soybean, corn, sunflower, cotton, safflower, canola and kelp.

11. The aquaculture feed as claimed in claim 1, or agriculture feed as claimed in claim 4, or human food as claimed in claim 7, wherein the therapeutic protein is an antibody specific for bacteria or virus causing disease in the respective aquaculture or agriculture species or human patient.

12. A method of delivering therapeutic proteins to a non-human animal comprising administering to said non-human animal a feed comprising biomass of an organism expressing a non-native therapeutic protein.
13. The method of claim 12, wherein the non-human animal is subjected to intensive agricultural practices.
14. The method of claim 12, wherein the non-human animal comprises fish or shellfish in aquaculture.
15. The method of claim 12, wherein the organism is infected by a recombinant virus which encodes the therapeutic protein and the therapeutic protein is expressed recombinantly.
16. The method of claim 12, wherein the therapeutic protein is a protein which inhibits growth or replication of *Vibrio* species *in vitro*.
17. The method of claim 12, wherein the therapeutic protein is a protein which inhibits Taura or White spot virus infection in shrimp.
18. The method of claim 12, wherein the therapeutic protein is a recombinantly expressed antibody or fragment thereof.

19. The method of claim 12, wherein the recombinantly expressed antibody or fragment thereof specifically binds to an infectious agent of disease in the non-human animal.
20. A method of delivering therapeutic proteins to crustaceans comprising infecting said crustaceans with a recombinant *Autographa californica* nuclear polyhedrosis virus and feeding said crustaceans edible material containing said virus.
21. The method of claim 20, wherein the source of said virus is the supernatant of cultured cells infected with said virus.
22. The method of claim 20, wherein the source of said virus is cultured cells infected with said virus.




FIGURE 1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/27198

A. CLASSIFICATION OF SUBJECT MATTER												
IPC(7) : A23K 1/18; A01K 67/00; A01H 1/00												
US CL : 426/805; 426/807; 800/8; 800/278												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols) U.S. : 426/805; 426/807; 800/8; 800/278												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X	MASON, H.S. et al. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. May 1996, Vol. 93, pages 5335-5340, entire document.	1,2,4,5,7,8,10,12 ----- 14										

Y												
X	MODELSKA, A. et al. Immunization against rabies with plant derived antigen. Proc. Natl. Acad. Sci. March 1998, Vol. 95, pages 2481-2485, entire document.	1-9,12,15 ----- 11,18,19,14										

Y												
X	YU et al. A plant-based multicomponent vaccine protects mice from enteric disease. Nature Biotech. June 2001, Vol. 19, pages 548-552, entire document.	1,2,4,5,7,8,13										
X	US 5,863,775 A (ATKINSON et al.) 26 January 1999 (26.01.1999), col.5, lines 61-65; col. 9, lines 44-45; col. 10, lines 14-25, col. 16, lines 56-60; col. 17, lines 62-67, col. 28, lines 41-42.	1,2,4,5,7,8,13										
Y	US 5,202,422 A (HIATT et al.) 13 April 1993 (13.04.1993), col. 3, lines 37-43; col.19, lines 42-45.	11,18,19										
Y	US 3,889,007 A (GUNTER et al.) 10 June 1975 (10.06.1975), entire document.	14										
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.												
* Special categories of cited documents: <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"B" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 10 December 2002 (10.12.2002)		Date of mailing of the international search report 30 DEC 2002										
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer <i>Valerie Bertoglio</i> Telephone No. 703-308-1234										

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/27198

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,618,574 A (BUNCH) 08 April 1997 (08.04.1997), entire document.	14
A	ARAKAWA et al. Plants are not just passive creatures. Nature Medicine. May 1998, Vol. 4, pages 550-551.	1-23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/27198

Continuation of Item 4 of the first sheet:

Title is too long, PCT Rule 4.3, suggested Title:

"Delivery of disease control using nutritional feeds containing bioactive proteins"

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Search Authority has found 4 inventions claimed in the International Application covered by the claims indicated below:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1,4,7,10,11, drawn to a feed containing biomass of a nonrecombinant plant.

Group II, claim(s) 1,4,7,11, drawn to a feed containing biomass of a nonrecombinant animal.

Group III, claim(s) 1,4,7,11, drawn to a feed containing biomass of a nonrecombinant insect.

Group IV, claim(s) 2,3,5,6,8,9,12-22, drawn to a feed containing biomass of a recombinant organism and a method of delivering therapeutic proteins through the feed.

1. This International Search Authority considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2, and 13.3) for the reasons indicated below:

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Unity of invention between different categories of inventions will only be found to exist if the specific combinations of inventions are present. Those combinations include:

- 1) A product and a special process of manufacture of said product.
- 2) A product and a process of use of said product.
- 3) A product, a special process of manufacture of said product, and a process of use of said product.
- 4) A process and an apparatus specially designed to carry out said process.
- 5) A product, a special process of manufacture of said product, and an apparatus specially designed to carry out said process.

The allowed combinations do not include multiple products, multiple methods of using said products, and methods of making multiple products as claimed in the instant application, see MPEP § 1850. Groups I, -IV represent different products with distinct material compositions, uses, and technical considerations.

If Applicant elects Groups I, II or III, claims 1,4,7, and 11 will be searched as they pertain to the elected Group.